Alphatec Holdings, Inc. 10-Q — AI Bull & Bear Analysis

The Q1 2026 filing reveals a company in a high-stakes transition from a growth-at-all-costs startup to a scalable medical technology firm. The core business is healthy, with double-digit revenue growth and improving gross margins, but the bottom line remains elusive due to high overhead and the lingering costs of a complex debt stack. The shift from positive to negative cash flow in the short term is offset by the strategic decision to invest in surgical instruments to support growth. Ultimately, the investment thesis hinges on the execution of the new JPMorgan credit facility. By replacing the expensive Braidwell loan, ATEC is attempting to buy time to reach an EBITDA inflection point. If the company can maintain its 14% growth rate while stabilizing SG&A, the restructured balance sheet will provide the necessary runway. However, investors must weigh this potential against the risks of inventory obsolescence and the continued burn of cash in a high-interest-rate environment.